[The changes in the brain's electrical activity in children with cerebral palsy during the complex rehabilitation].

Ukhanova TA, Gorbunov FE, Dement'eva EV, Volkova EA, Novikova EE

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2012

PMID23250594PepBankPUB-23250594

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with cerebral palsy, complex instruction, modeling and shape recognition skills occurred in 66% with Cortexin plus MENS versus 50% with MENS.
In plain wordsIn children with cerebral palsy, instruction, modeling and shape recognition skills occurred in 66% with Cortexin plus MENS versus 50% with MENS.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseComplex instructions, modeling and geometric form recognition
Study
n = 74
Comparator
MENS plus standard treatment
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
10 mg · intramuscular · Two courses of 10 injectionsAs given in this study (human).
Measurements
Complex instruction and modeling skills
66%
Cortexin plus MENS
Complex instruction and modeling skills
50%
MENS plus standard treatment
Source sentences
Summary
To the end of the rehabilitation program, positive changes were found: 50% patients of group I, 66% patients of group II and 16% patients of group III could perform complex instructions and acquired skills in modeling and recognition of geometric forms.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred and five children, aged from 3 to 7 years, with the diagnosis "spastic diplegia cerebral palsy" were treated.
Summary · context
Patients were stratified into three groups: group I (n=36) received three courses of microcurrent therapy (MENS) in addition to standard treatment; group II (n=38) received three courses of MENS in the combination with two treatment courses with the nootropic drug cortexin; children of group III (n=…
Summary · context
Cortexin was introduced intramuscular in dosage 10 mg, the treatment course consisted of 10 injections.
Report a problemFND-2325059401
02HumanNon-randomized trialEfficacy outcome
In children with spastic diplegia cerebral palsy, brain electrical activity improved in 82% with Cortexin plus MENS versus 75% with MENS.
In plain wordsIn children with cerebral palsy, brain electrical activity improved in 82% with Cortexin plus MENS versus 75% with MENS.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreasePositive brain electrical activity changes
Study
n = 74
Comparator
MENS plus standard treatment
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
10 mg · intramuscular · Two courses of 10 injectionsAs given in this study (human).
Measurements
Positive brain electrical activity changes
82%
Cortexin plus MENS
Positive brain electrical activity changes
75%
MENS plus standard treatment
Source sentences
Summary
Positive changes in the brain's electrical activity were found in 75% of children in group I, in 82% of children in group II and in 64% of children in group III.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred and five children, aged from 3 to 7 years, with the diagnosis "spastic diplegia cerebral palsy" were treated.
Summary · context
Patients were stratified into three groups: group I (n=36) received three courses of microcurrent therapy (MENS) in addition to standard treatment; group II (n=38) received three courses of MENS in the combination with two treatment courses with the nootropic drug cortexin; children of group III (n=…
Summary · context
Cortexin was introduced intramuscular in dosage 10 mg, the treatment course consisted of 10 injections.
Report a problemFND-2325059403

Studies that did not test the peptide alone2

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

03HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome
In children with cerebral palsy, instruction, modeling and shape recognition skills occurred in 66% with Cortexin plus MENS versus 16% with standard therapy.
In plain wordsIn children with cerebral palsy, instruction, modeling and shape recognition skills occurred in 66% with Cortexin plus MENS versus 16% with standard therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseComplex instructions, modeling and geometric form recognition
Study
n = 69
Comparator
Standard therapy using massage and gymnastics
Outcome group
Cognition and memory · Nervous system and cognition
Measurements
Complex instruction and modeling skills
66%
Cortexin plus MENS
Complex instruction and modeling skills
16%
Standard therapy
Source sentences
Summary
To the end of the rehabilitation program, positive changes were found: 50% patients of group I, 66% patients of group II and 16% patients of group III could perform complex instructions and acquired skills in modeling and recognition of geometric forms.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred and five children, aged from 3 to 7 years, with the diagnosis "spastic diplegia cerebral palsy" were treated.
Summary · context
Patients were stratified into three groups: group I (n=36) received three courses of microcurrent therapy (MENS) in addition to standard treatment; group II (n=38) received three courses of MENS in the combination with two treatment courses with the nootropic drug cortexin; children of group III (n=…
Summary · context
Cortexin was introduced intramuscular in dosage 10 mg, the treatment course consisted of 10 injections.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-2325059402
04HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome
In children with spastic diplegia cerebral palsy, brain electrical activity improved in 82% with Cortexin plus MENS versus 64% with standard therapy.
In plain wordsIn children with cerebral palsy, brain electrical activity improved in 82% with Cortexin plus MENS versus 64% with standard therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreasePositive brain electrical activity changes
Study
n = 69
Comparator
Standard therapy using massage and gymnastics
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
Positive brain electrical activity changes
82%
Cortexin plus MENS
Positive brain electrical activity changes
64%
Standard therapy
Source sentences
Summary
Positive changes in the brain's electrical activity were found in 75% of children in group I, in 82% of children in group II and in 64% of children in group III.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred and five children, aged from 3 to 7 years, with the diagnosis "spastic diplegia cerebral palsy" were treated.
Summary · context
Patients were stratified into three groups: group I (n=36) received three courses of microcurrent therapy (MENS) in addition to standard treatment; group II (n=38) received three courses of MENS in the combination with two treatment courses with the nootropic drug cortexin; children of group III (n=…
Summary · context
Cortexin was introduced intramuscular in dosage 10 mg, the treatment course consisted of 10 injections.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-2325059404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.